| Jun 6 |
Why Is Apellis Pharmaceuticals (APLS) Down 1.9% Since Last Earnings Report?
|
| Jun 5 |
Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference
|
| May 27 |
Apellis (APLS) Posts Upbeat One-Year Kidney Diseases Study Data
|
| May 27 |
Apellis and Sobi report data from Phase II C3 glomerulopathy trial
|
| May 24 |
Apellis Pharma up on phase 2 data for kidney disease treatment pegcetacoplan
|
| May 24 |
Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress
|
